Aaron Sverdlov, Co-Director of the Newcastle Centre of Excellence in Cardio-Oncology at Hunter Medical Research Institute (HMRI), shared a post by ESC Council of Cardio-Oncology on LinkedIn:
“Dear Colleagues.
If you are working in Breast Cancer or Cardio Oncology, please consider participating in brief research survey ‘International Survey on Cardiac Monitoring in Individuals with Metastatic HER-2 Positive Breast Cancer’.
It is led by Susan Dent, MD FRCPC, Professor in Oncology, Director of the Cardio-Oncology Program, as well as Director of the Judy DiMarzo Cancer Institute Survivorship Program.
The survey takes approximately 5-10 minutes to complete. Participation is voluntary, anonymous, and there is no compensation.
Principal Investigator: Susan Dent, MD FRCPC FIC‑OS
Sponsoring Institution: University of Rochester Medical Center (URMC)
Study Title: International Survey on Cardiac Monitoring in Individuals with Metastatic HER‑2 Positive Breast Cancer
Primary Objective:
The purpose of this study is to determine current practices for cardiac monitoring in individuals receiving cancer therapy for HER-2 positive metastatic breast cancer. This survey aims to capture real-world practices and referral patterns for cardiac monitoring in this patient population including:
- Monoclonal antibodies (eg trastuzumab, pertuzumab).
- Antibody-drug conjugates (eg T-DM1, T-DXd).
- Oral HER-2 targeted tyrosine kinase inhibitors (eg lapatinib, neratinib).
All responses are anonymous and will be used for research purposes only.
To participate in our study, please click on the link (deadline April 30):
Help us improve care of people living with Breast Cancer.”
Other articles about Breast Cancer on OncoDaily.